Literature DB >> 10066422

Uptake of liposomes containing phosphatidylserine by liver cells in vivo and by sinusoidal liver cells in primary culture: in vivo-in vitro differences.

J A Kamps1, H W Morselt, G L Scherphof.   

Abstract

The interaction with liver cells of liposomes containing different mol fractions of phosphatidylserine was investigated in vivo and in vitro. Increasing the amount of liposomal phosphatidylserine from 10 to 30 mol% leads to a faster blood disappearance of the liposomes. Within the liver, which is mainly responsible for this elimination, these liposomes are only taken up by the hepatocytes and Kupffer cells. By contrast, sinusoidal endothelial cells, in vitro, do bind and internalize liposomes containing >/=30% phosphatidylserine at least as actively as Kupffer cells. The uptake by endothelial and Kupffer cells is inhibited by poly(inosinic acid) and other anionic macromolecules, suggesting the involvement of scavenger receptors. The lack of liposome uptake by endothelial cells under in vivo conditions can be attributed to plasma effects since addition of various sera caused severe reduction of in vitro uptake of liposomes. In vivo the phosphatidylserine head groups may be masked by plasma proteins adsorbed to the liposomal surface, thus preventing recognition by receptors, which are intrinsically able to recognize phosphatidylserine. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10066422     DOI: 10.1006/bbrc.1999.0290

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups.

Authors:  S M Moghimi; A C Hunter
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

2.  Interaction of cationic colloids at the surface of J774 cells: a kinetic analysis.

Authors:  P Chenevier; B Veyret; D Roux; N Henry-Toulmé
Journal:  Biophys J       Date:  2000-09       Impact factor: 4.033

3.  Nanoprobes with near-infrared persistent luminescence for in vivo imaging.

Authors:  Quentin le Masne de Chermont; Corinne Chanéac; Johanne Seguin; Fabienne Pellé; Serge Maîtrejean; Jean-Pierre Jolivet; Didier Gourier; Michel Bessodes; Daniel Scherman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

4.  MARCO regulates early inflammatory responses against influenza: a useful macrophage function with adverse outcome.

Authors:  Sanjukta Ghosh; David Gregory; Alexia Smith; Lester Kobzik
Journal:  Am J Respir Cell Mol Biol       Date:  2011-05-11       Impact factor: 6.914

5.  Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates.

Authors:  Matthew P Kosloski; Aaron Peng; Prashant R Varma; Anas M Fathallah; Razvan D Miclea; Donald E Mager; Sathy V Balu-iyer
Journal:  Drug Deliv       Date:  2010-11-30       Impact factor: 6.419

6.  Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice.

Authors:  Aaron Peng; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2010-06-02       Impact factor: 4.009

Review 7.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

8.  Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.

Authors:  Genc Basha; Tatiana I Novobrantseva; Nicole Rosin; Yuen Yi C Tam; Ismail M Hafez; Matthew K Wong; Tsukasa Sugo; Vera M Ruda; June Qin; Boris Klebanov; Marco Ciufolini; Akin Akinc; Ying K Tam; Michael J Hope; Pieter R Cullis
Journal:  Mol Ther       Date:  2011-10-04       Impact factor: 11.454

Review 9.  Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems.

Authors:  Joseph A Piscatelli; Jisun Ban; Andrew T Lucas; William C Zamboni
Journal:  Pharmaceutics       Date:  2021-01-17       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.